Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
ScholarIQanswers from OpenAlex

Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China

PaperCitations, authors & open-access status

Cost-Effectiveness of Alectinib for Patients with Untreated ALK-Positive Non-Small Cell Lung Cancer in China is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 21 citations, 2019 year and closed oa status.

21
Citations
2019
Year
closed
OA Status

Related on ScholarIQ

Sheng Han
Author
Advances in Therapy
Journal
Lung Cancer Treatments and Mutations
Topic
Lung Cancer Treatments and Mutations
Topic
Economic and Financial Impacts of Cancer
Topic
Lung Cancer Diagnosis and Treatment
Topic
470M+ articles · free account